The US FDA approved a new treatment for non-small cell lung cancer - Tremelimumab + Durvalumab + platinum-based chemotherapy. The triple combination therapy significantly improves efficacy and patient survival and has a good safety profile.
Research suggests that gender-related differences in lung cancer survival are largely determined by known prognostic factors, suggesting an opportunity to explore gender differences in treatment preference, choice and accessibility.
